In 2014, HCRA was awarded $6.5 million (2014-2019) in research funding from Cancer Institute NSW as a Translational Cancer Research Centre (TCRC). In 2018, HCRA applied for an extension of funding until June 2021 and was awarded this extension of funding as a TCRC.
HCRA has streamlined its research efforts into three main flagship programs: Biomarkers and Targeted Therapies (BTT); Radiation Oncology, Cancer Imaging & Technology (ROCIT) and Implementation Science and Impact (ISI). The flagship programs operate as a mechanism for fostering communication and collaboration across the Hunter New England region, exploring and strengthening innovative research ideas and providing resources to HCRA members.
Each flagship program is led by a Steering Committee comprised of multidisciplinary expertise from across the research groups. The committees meet on a regular basis to discuss and identify local research needs and opportunities including support services and education, infrastructure, funding opportunities and peer-review of projects.
The BTT flagship program aims to generate new discoveries designed to improve practice via biomarker discovery and development and targeted therapies.
The ROCIT flagship program aims to improve clinical training, service delivery in cancer care and long-term survival via research advances in radiation oncology, cancer imaging and technology.